Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...

(MENAFN- EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Spravato, previously ...

Eldredge finally found relief. He said things immediately got better about six months ago when he tried Spravato. “It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal ...

Greenbrook treatment centers also offer SPRAVATO (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy ...

Greenbrook treatment centers also offer SPRAVATO ® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

Now, the FDA has also approved Spravato for treating adults with MDD who have not responded to at least two oral antidepressants. According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Morningstar brands and products Company Portfolio ...

SPRAVATO ® (esketamine ... PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds ...